Lund, Sweden — 3 March 2025 — Camurus (NASDAQ STO: CAMX) today announced that Jon Garay Alonso will be leaving the position as Chief Financial Officer (CFO) in the company for personal reasons. Jon will remain at Camurus until mid-August to ensure business continuity and a smooth transition. The recruitment process of a new CFO has been initiated.
“I would like to thank Jon Garay Alonso for his time at Camurus. As the company’s CFO, he has been a key member of our executive management, contributing to our continued successful development during the past three years”, says Fredrik Tiberg, Camurus’ President & CEO. “It has been a pleasure working with Jon and I wish him the best in his future.”
“I am grateful for the opportunity to have served as Camurus’ CFO, collaborating in the profitable growth journey and developing the company´s finance and IT organization. Camurus has a strong financial position, and I am confident about its capability to ensure continued growth and success”, says Jon Garay Alonso.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
This information was submitted for publication at 11:00 am CET on 3 March 2025.